Last reviewed · How we verify
NCT05662254: PERMA
PERsonalized Mood Augmentation Trial for Depressed Mood
NA trial testing Personalized Behavioral Intervention in Depression in 40 participants. Completed in 11 October 2024.
15 July 2024
Quick facts
| Lead sponsor | University of California, San Diego |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 June 2022 |
| Primary completion | 15 July 2024 |
| Estimated completion | 11 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Personalized Behavioral Intervention
Conditions studied
- Depression — all drugs for Depression →
Sponsor
University of California, San Diego
Who can join
15 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this open-label single-arm study is to test personalized behavioral intervention for depressed mood.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Personalized machine learning guided intervention for optimizing lifestyle behaviors in depression: a pilot study.
Nan J, Purpura S, Jaiswal S, Afshar H, et al · · 2026 · PMID 42151558 · DOI 10.1038/s44277-026-00062-3 -
Personalized Machine Learning guided Intervention for Optimizing Lifestyle Behaviors in Depression
Nan J, Purpura S, Jaiswal S, Afshar H, et al · · 2025 · DOI 10.1101/2025.11.04.25339502
Verify or expand the search:
- PubMed search for NCT05662254
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Personalized Behavioral Intervention
Trials testing the same drug.
- NCT02356757 — Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy · NA · completed
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
- NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
- NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
- NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
- NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05662254 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
- Last refreshed: 27 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05662254.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing